These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2103390)

  • 1. Induction and clinical utilization of lymphokine-activated killer cells in patients with gastrointestinal tract cancers.
    Tsugita M; Yamauchi K; Komatsu T; Suzuki H; Hanyu F
    J Gastroenterol Hepatol; 1990; 5(2):110-5. PubMed ID: 2103390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
    Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer.
    Ohta T; Kikuchi H; Ogata H; Iwata K; Yoshida K; Katayama K; Watanabe H
    Cancer; 1992 Aug; 70(4):741-8. PubMed ID: 1386555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y
    Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Locoregional adoptive immunotherapy using LAK cells and IL-2 against liver metastases from digestive tract cancer].
    Ueda Y; Sonoyama T; Itoi H; Fujiwara H; Fuji N; Itoh T; Fujiki H; Yamashita T; Yoshimura T; Harada S; Okugawa K; Yamagishi H
    Gan To Kagaku Ryoho; 2000 Oct; 27(12):1962-5. PubMed ID: 11086454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
    Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
    Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y; Tanaka T; Tanji Y; Fujiwara A; Taguchi T
    Biotherapy; 1994; 8(1):41-50. PubMed ID: 7547080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcatheter arterial injection of autologous lymphokine-activated killer (LAK) cells into patients with liver cancers.
    Komatsu T; Yamauchi K; Furukawa T; Obata H
    J Clin Immunol; 1990 May; 10(3):167-74. PubMed ID: 2164039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases.
    Keilholz U; Scheibenbogen C; Brado M; Georgi P; Maclachlan D; Brado B; Hunstein W
    Eur J Cancer; 1994; 30A(1):103-5. PubMed ID: 8142149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional administration of lymphokine-activated killer cells can be superior to intravenous application.
    Keilholz U; Schlag P; Tilgen W; Brado B; Galm F; Görich J; Kauffmann GW; Möller P; Schneider S; Hunstein W
    Cancer; 1992 Apr; 69(8):2172-5. PubMed ID: 1544123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
    Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A comparison of the suppressor and cytotoxic activities of the blood mononuclear cells during the adoptive immunotherapy of cancer patients using lymphokine-activated killers with a low dose of recombinant interleukin-2].
    Abronina IF; Kupriianova TA; Bolvachova AV; Bykovskaia SN; Dronova OM; Buachidze LI
    Biull Eksp Biol Med; 1991 Nov; 112(11):519-21. PubMed ID: 1839773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local adoptive immunotherapy using lymphokine-activated killer cells and interleukin-2 against malignant pleural mesothelioma: report of two cases.
    Yanagawa H; Sone S; Fukuta K; Nishioka Y; Ogura T
    Jpn J Clin Oncol; 1991 Oct; 21(5):377-83. PubMed ID: 1753419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphokine activated killer (LAK) cells in patients with gastrointestinal cancer.
    Monson JR; Ramsden CW; Giles GR; Brennan TG; Guillou PJ
    Gut; 1987 Nov; 28(11):1420-5. PubMed ID: 3501386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lymphokine-activated killer cell adoptive immunotherapy for cancer treatment and its significance].
    Toge T; Yamaguchi Y
    Hum Cell; 1992 Sep; 5(3):218-25. PubMed ID: 1334695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
    Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
    Guo YS; Xing ZL
    Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study.
    Ferlazzo G; Scisca C; Iemmo R; Cavaliere R; Quartarone G; Adamo V; Frazzetto G; Costa G; Melioli G
    J Immunother; 1997 Mar; 20(2):158-63. PubMed ID: 9087388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.